Genmab A/S (NASDAQ:GMAB) Sets New 52-Week High - Should You Buy?

Key Points

• Genmab shares reached a new 52-week high of $40.17, with the stock last trading at $39.67. Its 50-day and 200-day moving averages were $34.84 and $30.03, respectively.
• Analysts are generally bullish, with a consensus rating of “Moderate Buy” and an average price target of $43.39. Guggenheim raised its target to $54, while TD Cowen upgraded the stock to “buy.”
• Genmab exceeded quarterly expectations, reporting EPS of $0.54 versus the $0.37 consensus and revenue of $1.16 billion versus estimates of $1.12 billion. The biotechnology company develops antibody-based treatments, including DARZALEX, EPKINLY and Tivdak.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) reached a new 52-week high on Thursday. The stock traded as high as $40.17 and last traded at $39.67, with a volume of 2,043,779 shares. The stock had previously closed at $39.57.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Weiss Ratings raised Genmab A/S from a "hold (c)" rating to a "hold (c+)" rating in a report on Tuesday, September 1st. Morgan Stanley set a $42.00 price target on Genmab A/S in a report on Tuesday. Guggenheim increased their price objective on Genmab A/S from $45.00 to $54.00 and gave the company a "buy" rating in a research report on Monday, October 5th. New Street Research set a $43.00 price objective on shares of Genmab A/S in a research note on Wednesday, July 22nd. Finally, TD Cowen upgraded shares of Genmab A/S from a "hold" rating to a "buy" rating and raised their price objective for the stock from $32.00 to $43.00 in a research note on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Genmab A/S has a consensus rating of "Moderate Buy" and a consensus price target of $43.39.

Genmab A/S Price Performance

The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81. The stock's 50-day moving average price is $34.84 and its 200 day moving average price is $30.03. The firm has a market cap of $24.96 billion, a price-to-earnings ratio of 31.50, a price-to-earnings-growth ratio of 1.81 and a beta of 0.81.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.17. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.12 billion. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%. Equities research analysts predict that Genmab A/S Sponsored ADR will post 1.21 earnings per share for the current year.

Institutional Trading of Genmab A/S

A number of institutional investors and hedge funds have recently modified their holdings of the company. Personal CFO Solutions LLC lifted its position in Genmab A/S by 3.7% in the first quarter. Personal CFO Solutions LLC now owns 10,866 shares of the company's stock worth $292,000 after purchasing an additional 386 shares during the period. Versant Capital Management Inc boosted its stake in Genmab A/S by 4.5% during the third quarter. Versant Capital Management Inc now owns 12,235 shares of the company's stock worth $436,000 after buying an additional 523 shares in the last quarter. GAMMA Investing LLC boosted its stake in Genmab A/S by 16.4% during the second quarter. GAMMA Investing LLC now owns 3,978 shares of the company's stock worth $109,000 after buying an additional 561 shares in the last quarter. Summitry LLC increased its holdings in Genmab A/S by 5.3% in the 1st quarter. Summitry LLC now owns 11,170 shares of the company's stock valued at $300,000 after buying an additional 567 shares during the period. Finally, AdvisorShares Investments LLC increased its holdings in Genmab A/S by 2.2% in the 1st quarter. AdvisorShares Investments LLC now owns 30,853 shares of the company's stock valued at $828,000 after buying an additional 653 shares during the period. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab's marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.